LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 9 of total 9

Search options

  1. Book ; Online ; Thesis: Optimierung und Validierung eines SARS-CoV-2-N IgG Antikörper ELISA

    Schnurra, Carolin [Verfasser]

    2024  

    Author's details Carolin Schnurra
    Keywords Medizin, Gesundheit ; Medicine, Health
    Subject code sg610
    Language German
    Publisher Universitätsbibliothek Leipzig
    Publishing place Leipzig
    Document type Book ; Online ; Thesis
    Database Digital theses on the web

    More links

    Kategorien

  2. Article ; Online: Comparison of the diagnostic sensitivity of SARS-CoV-2 nucleoprotein and glycoprotein-based antibody tests.

    Schnurra, Carolin / Reiners, Nina / Biemann, Ronald / Kaiser, Thorsten / Trawinski, Henning / Jassoy, Christian

    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology

    2020  Volume 129, Page(s) 104544

    Abstract: The emergence of the severe acute respiratory syndrome coronavirus-2 (SARS CoV-2) has been followed by the rapid development of antibody tests. To assess the utility of the tests for clinical use and seroepidemiologic studies, we examined the sensitivity ...

    Abstract The emergence of the severe acute respiratory syndrome coronavirus-2 (SARS CoV-2) has been followed by the rapid development of antibody tests. To assess the utility of the tests for clinical use and seroepidemiologic studies, we examined the sensitivity of commercial antibody tests from Roche, Abbott, Novatec, Virotech Siemens, Euroimmun, and Mediagnost in a prospective diagnostic study. The tests were evaluated with 73 sera from SARS CoV-2 RNA positive individuals with mild to moderate disease or asymptomatic infection. Sera were obtained at 2-3 weeks (N = 25) or > 4 weeks (N = 48) after symptom onset and viral RNA test. The overall sensitivity of the tests ranged from 64.4-93.2%. The most sensitive assays recognized 95.8-100 % of the sera obtained after 4 weeks or later. Sera drawn at 2-3 weeks were recognized with lower sensitivity indicating that the optimal time point for serologic testing is later than 3 weeks after onset of the disease. Nucleoprotein- and glycoproteinbased assays had similar sensitivity indicating that tests with both antigens are suitable for serological diagnostics. Breakdown of the test results showed that nucleoprotein- and glycoprotein-based tests of comparable sensitivity reacted with different sets of sera. The observation indicates that a combination of nucleoprotein- and glycoprotein-based tests would increase the percentage of positive results.
    MeSH term(s) Antibodies, Viral/blood ; Antigens, Viral/immunology ; Betacoronavirus/immunology ; Betacoronavirus/isolation & purification ; COVID-19 ; COVID-19 Testing ; Clinical Laboratory Techniques/methods ; Coronavirus Infections/diagnosis ; Glycoproteins/immunology ; Humans ; Nucleoproteins/immunology ; Pandemics ; Pneumonia, Viral/diagnosis ; Prospective Studies ; SARS-CoV-2 ; Sensitivity and Specificity ; Serologic Tests/methods ; Time Factors ; Viral Structural Proteins/immunology
    Chemical Substances Antibodies, Viral ; Antigens, Viral ; Glycoproteins ; Nucleoproteins ; Viral Structural Proteins
    Keywords covid19
    Language English
    Publishing date 2020-07-06
    Publishing country Netherlands
    Document type Evaluation Study ; Journal Article
    ZDB-ID 1446080-4
    ISSN 1873-5967 ; 1386-6532
    ISSN (online) 1873-5967
    ISSN 1386-6532
    DOI 10.1016/j.jcv.2020.104544
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Performance of a SARS CoV-2 antibody ELISA based on simultaneous measurement of antibodies against the viral nucleoprotein and receptor-binding domain.

    Reiners, Nina / Schnurra, Carolin / Trawinski, Henning / Kannenberg, Judith / Hermsdorf, Thomas / Aebischer, Andrea / Schöneberg, Torsten / Reiche, Sven / Jassoy, Christian

    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology

    2021  Volume 40, Issue 12, Page(s) 2645–2649

    Abstract: SARS CoV-2 antibody assays measure antibodies against the viral nucleoprotein (NP) or spike protein. The study examined if testing of antibodies against both antigens increases the diagnostic sensitivity. Sera (N=98) from infected individuals were tested ...

    Abstract SARS CoV-2 antibody assays measure antibodies against the viral nucleoprotein (NP) or spike protein. The study examined if testing of antibodies against both antigens increases the diagnostic sensitivity. Sera (N=98) from infected individuals were tested with ELISAs based on the NP, receptor-binding domain (RBD), or both proteins. The AUROCs were 0.958 (NP), 0.991 (RBD), and 0.992 (NP/RBD). The RBD- and NP/RBD-based ELISAs showed better performance than the NP-based assay. Simultaneous testing for antibodies against NP and RBD increased the number of true and false positives. If maximum diagnostic sensitivity is required, the NP/RBD-based ELISA is preferable. Otherwise, the RBD-based ELISA is sufficient.
    MeSH term(s) Antibodies, Viral/blood ; COVID-19/blood ; COVID-19/virology ; COVID-19 Testing/methods ; Enzyme-Linked Immunosorbent Assay/methods ; Humans ; Nucleoproteins/chemistry ; Nucleoproteins/immunology ; Protein Domains ; SARS-CoV-2/chemistry ; SARS-CoV-2/immunology
    Chemical Substances Antibodies, Viral ; Nucleoproteins
    Language English
    Publishing date 2021-06-04
    Publishing country Germany
    Document type Evaluation Study ; Journal Article
    ZDB-ID 603155-9
    ISSN 1435-4373 ; 0934-9723 ; 0722-2211
    ISSN (online) 1435-4373
    ISSN 0934-9723 ; 0722-2211
    DOI 10.1007/s10096-021-04284-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Comparison of the diagnostic sensitivity of SARS-CoV-2 nucleoprotein and glycoprotein-based antibody tests

    Schnurra, Carolin / Reiners, Nina / Biemann, Ronald / Kaiser, Thorsten / Trawinski, Henning / Jassoy, Christian

    Journal of Clinical Virology

    2020  Volume 129, Page(s) 104544

    Keywords Virology ; Infectious Diseases ; covid19
    Language English
    Publisher Elsevier BV
    Publishing country us
    Document type Article ; Online
    ZDB-ID 1446080-4
    ISSN 1873-5967 ; 1386-6532
    ISSN (online) 1873-5967
    ISSN 1386-6532
    DOI 10.1016/j.jcv.2020.104544
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  5. Article: Comparison of the diagnostic sensitivity of SARS-CoV-2 nucleoprotein and glycoprotein-based antibody tests

    Schnurra, Carolin / Reiners, Nina / Biemann, Ronald / Kaiser, Thorsten / Trawinski, Henning / Jassoy, Christian

    J Clin Virol

    Abstract: The emergence of the severe acute respiratory syndrome coronavirus-2 (SARS CoV-2) has been followed by the rapid development of antibody tests. To assess the utility of the tests for clinical use and seroepidemiologic studies, we examined the sensitivity ...

    Abstract The emergence of the severe acute respiratory syndrome coronavirus-2 (SARS CoV-2) has been followed by the rapid development of antibody tests. To assess the utility of the tests for clinical use and seroepidemiologic studies, we examined the sensitivity of commercial antibody tests from Roche, Abbott, Novatec, Virotech Siemens, Euroimmun, and Mediagnost in a prospective diagnostic study. The tests were evaluated with 73 sera from SARS CoV-2 RNA positive individuals with mild to moderate disease or asymptomatic infection. Sera were obtained at 2-3 weeks (N = 25) or > 4 weeks (N = 48) after symptom onset and viral RNA test. The overall sensitivity of the tests ranged from 64.4-93.2%. The most sensitive assays recognized 95.8-100 % of the sera obtained after 4 weeks or later. Sera drawn at 2-3 weeks were recognized with lower sensitivity indicating that the optimal time point for serologic testing is later than 3 weeks after onset of the disease. Nucleoprotein- and glycoproteinbased assays had similar sensitivity indicating that tests with both antigens are suitable for serological diagnostics. Breakdown of the test results showed that nucleoprotein- and glycoprotein-based tests of comparable sensitivity reacted with different sets of sera. The observation indicates that a combination of nucleoprotein- and glycoprotein-based tests would increase the percentage of positive results.
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #634673
    Database COVID19

    Kategorien

  6. Article ; Online: Sensitivity of SARS-CoV-2 antibody tests with late convalescent sera.

    Kannenberg, Judith / Schnurra, Carolin / Reiners, Nina / Henschler, Reinhard / Buhmann, Raymund / Kaiser, Thorsten / Biemann, Ronald / Hönemann, Mario / Ackermann, Grit / Trawinski, Henning / Jassoy, Christian

    Journal of clinical virology plus

    2021  Volume 1, Issue 3, Page(s) 100038

    Abstract: SARS-CoV-2-specific IgM antibodies wane during the first three months after infection and IgG antibody levels decline. This may limit the ability of antibody tests to identify previous SARS-CoV-2 infection at later time points. To examine if the ... ...

    Abstract SARS-CoV-2-specific IgM antibodies wane during the first three months after infection and IgG antibody levels decline. This may limit the ability of antibody tests to identify previous SARS-CoV-2 infection at later time points. To examine if the diagnostic sensitivity of antibody tests falls off, we compared the sensitivity of two nucleoprotein-based antibody tests, the Roche Elecsis II Anti-SARS-CoV-2 and the Abbott SARS-CoV-2 IgG assay and three glycoprotein-based tests, the Abbott SARS-CoV-2 IgG II Quant, Siemens Atellica IM COV2T and Euroimmun SARS-CoV-2 assay with 53 sera obtained 6 months after SARS-CoV-2 infection. The sensitivity of the Roche, Abbott SARS-CoV-2 IgG II Quant and Siemens antibody assays was 94.3% (95% confidence interval (CI) 84.3-98.8%), 98.1 % (95% CI: 89.9-100%) and 100 % (95% CI: 93.3-100%). The sensitivity of the N-based Abbott SARS-CoV-2 IgG and the glycoprotein-based Euroimmun ELISA was 45.3 % (95% CI: 31.6-59.6%) and 83.3% (95% CI: 70.2-91.9%). The nucleoprotein-based Roche and the glycoprotein-based Abbott receptor binding domain (RBD) and Siemens tests were more sensitive than the N-based Abbott and the Euroimmun antibody tests (
    Language English
    Publishing date 2021-08-18
    Publishing country England
    Document type Journal Article
    ISSN 2667-0380
    ISSN (online) 2667-0380
    DOI 10.1016/j.jcvp.2021.100038
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Performance of a SARS CoV-2 antibody ELISA based on simultaneous measurement of antibodies against the viral nucleoprotein and receptor-binding domain

    Reiners, Nina / Schnurra, Carolin / Trawinski, Henning / Kannenberg, Judith / Hermsdorf, Thomas / Aebischer, Andrea / Schöneberg, Torsten / Reiche, Sven / Jassoy, Christian

    Brief Report

    2021  

    Abstract: SARS CoV-2 antibody assays measure antibodies against the viral nucleoprotein (NP) or spike protein. The study examined if testing of antibodies against both antigens increases the diagnostic sensitivity. Sera (N=98) from infected individuals were tested ...

    Abstract SARS CoV-2 antibody assays measure antibodies against the viral nucleoprotein (NP) or spike protein. The study examined if testing of antibodies against both antigens increases the diagnostic sensitivity. Sera (N=98) from infected individuals were tested with ELISAs based on the NP, receptor-binding domain (RBD), or both proteins. The AUROCs were 0.958 (NP), 0.991 (RBD), and 0.992 (NP/RBD). The RBD- and NP/RBD-based ELISAs showed better performance than the NP-based assay. Simultaneous testing for antibodies against NP and RBD increased the number of true and false positives. Ifmaximumdiagnostic sensitivity is required, the NP/RBD-based ELISA is preferable. Otherwise, the RBD-based ELISA is sufficient.
    Keywords Text ; ddc:630 ; SARS CoV-2 -- Nucleoprotein -- Receptor-binding domain -- COVID-19 -- Antibodies -- ELISA
    Language English
    Publishing date 2021-06-04
    Publishing country de
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  8. Article ; Online: Sensitivity of SARS-CoV-2 antibody tests with late convalescent sera

    Kannenberg, Judith / Schnurra, Carolin / Reiners, Nina / Henschler, Reinhard / Buhmann, Raymund / Kaiser, Thorsten / Biemann, Ronald / Hoenemann, Mario / Ackermann, Grit / Trawinski, Henning / Jassoy, Christian

    medRxiv

    Abstract: SARS-CoV-2-specific IgM antibodies wane during the first three months after infection and IgG antibody levels decline. This may limit the ability of antibody tests to identify previous SARS CoV-2 infection at later time points. To examine if the ... ...

    Abstract SARS-CoV-2-specific IgM antibodies wane during the first three months after infection and IgG antibody levels decline. This may limit the ability of antibody tests to identify previous SARS CoV-2 infection at later time points. To examine if the sensitivity of antibody tests falls off, we compared the sensitivity of two nucleoprotein-based antibody tests, the Roche Elecsis II Anti-SARS-CoV-2 and the Abbott SARS-CoV-2 IgG assay and three glycoprotein-based tests, the Abbott SARS-CoV-2 IgG II Quant, Siemens Atellica IM COV2T and Euroimmun SARS-CoV-2 assay with 56 sera obtained 6-8 months after SARS-CoV-2 infection. The sensitivity of the Roche, Abbott SARS-CoV-2 IgG II Quant and Siemens antibody assays was 94.6 % (95% confidence interval (CI) 85.1-98.9 %), 98.2 % (95% CI: 90.4-99.9 %) and 100 % (95% CI: 93.6-100 %). The sensitivity of the N-based Abbott SARS-CoV-2 IgG and the glycoprotein-based Euroimmun ELISA was 48.2 % (95% CI: 34.7-62.0 %) and 83.9 % (95% CI: 71.7-92.4 %). The nucleoprotein-based Roche and the glycoprotein-based Abbott RBD and Siemens tests were more sensitive than the N-based Abbott and the Euroimmun antibody tests (p=0.0001 to p=0.039). The N-based Abbott antibody test was less sensitive 6-8 months than 4-10 weeks after SARS-CoV-2 infection (p = 0.0002). The findings show that most SARS CoV-2 antibody assays correctly identified previous infection 6-8 months after infection. The sensitivity of pan-Ig antibody tests was not reduced at 6-8 months when IgM antibodies have usually disappeared. However, one of the nucleoprotein-based antibody tests significantly lost sensitivity over time.
    Keywords covid19
    Language English
    Publishing date 2021-07-07
    Publisher Cold Spring Harbor Laboratory Press
    Document type Article ; Online
    DOI 10.1101/2021.07.07.21259772
    Database COVID19

    Kategorien

  9. Article: Epidermal growth factor and trefoil factor family 2 synergistically trigger chemotaxis on BEAS-2B cells via different signaling cascades.

    Chwieralski, Caroline E / Schnurra, Ingo / Thim, Lars / Hoffmann, Werner

    American journal of respiratory cell and molecular biology

    2004  Volume 31, Issue 5, Page(s) 528–537

    Abstract: Injured areas of the respiratory epithelium are subject to rapid repair by the migration of adjacent epithelial cells, a process termed "restitution". Rapid re-epithelialization is promoted by interactions between migrating cells and the extracellular ... ...

    Abstract Injured areas of the respiratory epithelium are subject to rapid repair by the migration of adjacent epithelial cells, a process termed "restitution". Rapid re-epithelialization is promoted by interactions between migrating cells and the extracellular matrix proteins. Furthermore, epidermal growth factor (EGF) as well as trefoil factor family (TFF) peptides are well known regulators of epithelial restitution due to their motogenic effects. Migration of the human bronchial epithelial cell line BEAS-2B in modified Boyden chambers was used as a model system for airway restitution. EGF or recombinant human TFF2 or TFF3 showed mainly chemotactic activity. The motogenic response was strictly dependent upon a haptotactic substrate, but to different degrees. EGF induced phosphorylation of extracellular signal-regulated kinases (ERK) 1/2, c-Jun-N-terminal kinase, p38, Akt, and p70S6K in BEAS-2B cells. Using specific inhibitors, the signaling cascades responsible for the motogenic response were shown to differ drastically when EGF was compared with TFF2. The motogenic effect of TFF2 was previously demonstrated to depend on ERK1/2 and protein kinase C activation; whereas the EGF-triggered motogenic response was completely independent of ERK1/2 activation but sensitive to the inhibition of phosphoinositide 3-kinase, p38, protein kinase C, or nuclear factor kappaB. However, the motogenic effects of EGF and TFF2 are additive. These data suggest that luminal EGF and TFF peptides can act synergistically in the human respiratory epithelium to enhance rapid repair processes in the course of diseases such as asthma.
    MeSH term(s) Cell Line ; Cell Movement ; Chemotaxis ; Dimerization ; Dose-Response Relationship, Drug ; Enzyme Activation ; Epidermal Growth Factor/metabolism ; Epidermal Growth Factor/physiology ; Humans ; Immunoblotting ; JNK Mitogen-Activated Protein Kinases/metabolism ; Mucins/physiology ; Muscle Proteins/physiology ; NF-kappa B/metabolism ; Peptides/chemistry ; Peptides/physiology ; Phosphorylation ; Protein Kinase C/metabolism ; Protein Kinase C-alpha ; Protein-Serine-Threonine Kinases/metabolism ; Proto-Oncogene Proteins/metabolism ; Proto-Oncogene Proteins c-akt ; Recombinant Proteins/chemistry ; Respiratory Mucosa/cytology ; Ribosomal Protein S6 Kinases, 70-kDa/metabolism ; Signal Transduction ; Subcellular Fractions/metabolism ; Time Factors ; Trefoil Factor-2 ; Trefoil Factor-3 ; p38 Mitogen-Activated Protein Kinases/metabolism
    Chemical Substances Mucins ; Muscle Proteins ; NF-kappa B ; Peptides ; Proto-Oncogene Proteins ; Recombinant Proteins ; TFF2 protein, human ; TFF3 protein, human ; Trefoil Factor-2 ; Trefoil Factor-3 ; Epidermal Growth Factor (62229-50-9) ; AKT1 protein, human (EC 2.7.11.1) ; Protein-Serine-Threonine Kinases (EC 2.7.11.1) ; Proto-Oncogene Proteins c-akt (EC 2.7.11.1) ; Ribosomal Protein S6 Kinases, 70-kDa (EC 2.7.11.1) ; PRKCA protein, human (EC 2.7.11.13) ; Protein Kinase C (EC 2.7.11.13) ; Protein Kinase C-alpha (EC 2.7.11.13) ; JNK Mitogen-Activated Protein Kinases (EC 2.7.11.24) ; p38 Mitogen-Activated Protein Kinases (EC 2.7.11.24)
    Language English
    Publishing date 2004-11
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1025960-0
    ISSN 1535-4989 ; 1044-1549
    ISSN (online) 1535-4989
    ISSN 1044-1549
    DOI 10.1165/rcmb.2003-0433OC
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top